No

Antineoplastic Agent, Miscellaneous; Estrogen Derivative

Palliative treatment of advanced, inoperable carcinoma of the prostate

X

Known or suspected estrogen-dependent neoplasm, carcinoma of the breast, active thromboembolic disorders, hypersensitivity to estrogens or any component, pregnancy

Use with caution in patients with migraine, diabetes, cardiac, or renal impairment

>10%:

Cardiovascular: Peripheral edema

Endocrine & metabolic: Enlargement of breasts (female and male), breast tenderness

Gastrointestinal: Nausea, anorexia, bloating

1% to 10%:

Central nervous system: Headache

Endocrine & metabolic: Increased libido (female), decrease libido (male)

Gastrointestinal: Vomiting, diarrhea

<1%: Hypertension, thromboembolism, myocardial infarction, edema, depression, dizziness, anxiety, stroke, chloasma, melasma, rash, amenorrhea, alterations in frequency and flow of menses, decreased glucose tolerance, increased triglycerides and LDL, nausea, GI distress, cholestatic jaundice, intolerance to contact lenses, increased susceptibility to Candida infection, breast tumors

Toxicity is unlikely following single exposures of excessive doses

Any treatment following emesis and charcoal administration should be supportive and symptomatic

No data reported

After reconstitution, solution is stable for 10 days at room temperature and protected from direct light

Estrogens exert their primary effects on the interphase DNA-protein complex (chromatin) by binding to a receptor (usually located in the cytoplasm of a target cell) and initiating translocation of the hormone-receptor complex to the nucleus

90% of injected dose leaves bloodstream within 24 hours

Passive storage in reticuloendothelial system

Increasing the dose prolongs duration of action

Adults: Deep I.M.: 40 mg every 2-4 weeks or less frequently; maximum dose: 80 mg

May rarely cause anxiety, dizziness, or depression

None reported

No information available to require special precautions

No effects or complications reported

Women should inform their physicians if signs or symptoms of any of the following occur: thromboembolic or thrombotic disorders including sudden severe headache or vomiting, disturbance of vision or speech, loss of vision, numbness or weakness in an extremity, sharp or crushing chest pain, calf pain, shortness of breath, severe abdominal pain or mass, mental depression or unusual bleeding; women should discontinue taking the medication if they suspect they are pregnant or become pregnant

Powder for injection, as phosphate: 40 mg

Jeffrey LP, Chairman, National Study Commission on Cytotoxic Exposure. Position Statement. "The Handling of Cytotoxic Agents by Women Who Are Pregnant, Attempting to Conceive, or Breast-Feeding," January 12, 1987.